



Journal of **COMMERCIAL BIOTECHNOLOGY**

OCTOBER 2013

VOLUME 19 | NUMBER 4

ISSN: 1462-8732 / eISSN 1478-565X

WWW.COMMERCIALBIOTECHNOLOGY.COM

Journal of COMMERCIAL BIOTECHNOLOGY

VOLUME 19

NUMBER 4

OCTOBER 2013

Contents

Assessing the history and value of Human Genome Sciences <i>Laura M. McNamee, Fred D. Ledley</i>	3
Unaddressed implications of technology in global health <i>Bryan A. Liang</i>	11
Technology and global health: <i>Spy vs. Spy</i> and SPOCS to promote global drug supply safety <i>Thomas T. Kubic</i>	13
Dangerous science: Online promotion of unproven stem cell therapies and global health risks <i>Tim K. Mackey, Bryan A. Liang</i>	19
Protecting the U.S medicine supply: Integrating approaches to promote safety <i>John Theriault</i>	29
Motorcycle simulator technology and traffic-related injury prevention: Global health potential <i>James A. Balcius, Bryan A. Liang</i>	35
Technology and medicine: Academic dishonesty and risks to global health <i>Bryan A. Liang, Timothy K. Mackey, Kimberly M. Lovett</i>	42
Integrated outsourcing transforms and increases R&D productivity <i>Henry Levy</i>	49
Competition regulation and recombinant drugs in India <i>Padmavati Manchikanti</i>	55
An agile, cross-discipline model for developing bio-enterprise professionals <i>Moir A. Gunn, Jennifer Dever, Christina Tzagarakis-Foster, Paul Lorton, Jr., Kathleen Kane, Nola Masterson</i>	72

While every effort is made to see that no inaccurate data, opinion or statement appears in this journal, the Publishers and the Editors wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor(s) or advertiser(s) concerned. Accordingly, the Publishers, the Editors and their respective employees, officers and agents accept no liability whatsoever for the consequences of such inaccurate or misleading data, opinion or statement.